XML 16 R6.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Operating activities    
Net earnings (loss) $ 6,474 $ (1,221)
Noncash items:    
Depreciation and amortization 1,061 997
Deferred income taxes 64 (27)
Share-based compensation 375 372
Loss on sale of subsidiary and subsidiaries held for sale 15 7,086
Other, net 97 179
Net change in other operating items, net of effects from acquisitions and dispositions:    
Accounts receivable (4,462) (6,162)
Other assets (544) (1,927)
Medical costs payable 2,993 2,069
Accounts payable and other liabilities (607) (231)
Unearned revenues (10) 9
Cash flows from operating activities 5,456 1,144
Investing activities    
Purchases of investments (4,135) (4,798)
Sales of investments 3,185 2,976
Maturities of investments 2,167 2,314
Cash paid for acquisitions and other transactions, net of cash assumed (702) (3,006)
Purchases of property, equipment and capitalized software (898) (743)
Loans to care providers - cyberattack 0 (2,164)
Repayments of care provider loans - cyberattack 891 0
Other, net (582) (919)
Cash flows used for investing activities (74) (6,340)
Financing activities    
Common share repurchases (3,000) (3,072)
Cash dividends paid (1,912) (1,729)
Proceeds from common stock issuances 360 486
Repayments of long-term debt 0 (750)
Proceeds from short-term borrowings, net 3,911 6,189
Proceeds from issuance of long-term debt 0 5,925
Customer funds administered 1,245 1,745
Other, net (505) (563)
Cash flows from financing activities 99 8,231
Effect of exchange rate changes on cash and cash equivalents 15 (48)
Increase in cash and cash equivalents, including cash within businesses held for sale 5,496 2,987
Less: net increase in cash within businesses held for sale (91) 0
Net increase in cash and cash equivalents 5,405 2,987
Cash and cash equivalents, beginning of period 25,312 25,427
Cash and cash equivalents, end of period $ 30,717 $ 28,414